Skip to main content
DrugPrice

Orange Book Listing

The FDA's publication of approved drug products with therapeutic equivalence ratings and associated patent and exclusivity information, used to determine generic substitution.

How It Works

The "Approved Drug Products with Therapeutic Equivalence Evaluations," universally called the Orange Book for its historical cover color, is the FDA's authoritative list of approved small-molecule drugs and their generic equivalents. Published continuously since 1980 and updated daily online at fda.gov, the Orange Book serves three critical functions: (1) identifying FDA-approved drug products, (2) providing Therapeutic Equivalence codes (AA, AB, BC, etc.) that determine whether a generic is considered substitutable for the brand at the pharmacy counter, and (3) listing patents and exclusivities that affect generic entry timing. AB-rated generics are considered substitutable without prescriber intervention in most states; B-rated products require prescriber approval. Orange Book patent listings are submitted by innovator manufacturers under 21 CFR 314.53, and listings must claim either the drug substance, drug product, or method of use approved in the NDA. Improperly listed patents can be challenged through Paragraph IV certifications or FTC enforcement, the FTC's 2023 initiative on Orange Book patent listing challenged hundreds of patent listings (notably for Ozempic, Mounjaro, several combination inhalers) as improperly broad, delisting or narrowing many. Biologics are listed in the Purple Book (BLAs), not the Orange Book. DrugPrice's generic-watch page integrates Orange Book patent expiration data to project generic launch windows. Patent thickets (multiple overlapping patents with staggered expirations, as AbbVie used for Humira with 132 patents) can extend effective exclusivity well beyond any single patent's life.

Related Terms

  • FDA Approval, The process by which the U.S. Food and Drug Administration evaluates a drug's safety and efficacy through clinical trial data before allowing it to be marketed.
  • Abbreviated New Drug Application (ANDA), The FDA application pathway for generic drugs, which requires proving bioequivalence to the brand-name drug rather than repeating full clinical trials.
  • Patent Expiration, The date when a drug's patent protection ends, allowing generic or biosimilar manufacturers to produce competing versions.
  • Citizen Petition, A formal request filed with the FDA under 21 CFR 10.30 that can be used legitimately or as a delay tactic to slow generic drug approval by raising safety or bioequivalence questions.
  • Exclusivity Period, A period of market protection granted by the FDA (separate from patents) during which generic competitors cannot be approved, even if no patent exists.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.